Adaptive Radiation for Locally Advanced Pancreatic Cancer
This study is looking at a new way to give radiation called Adaptive Radiation Therapy (ART) for people with locally advanced pancreatic cancer that cannot be removed by surgery. ART creates a personalized radiation plan for each treatment session, which means the plan can change daily to target the tumor more precisely and protect healthy tissue nearby. The main goal is to see if ART can reduce side effects like stomach and bowel problems. To join, you must have pancreatic cancer that is locally advanced and unresectable. The study plans to enroll 16 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 16 participants.
- What's involved
- You would have CT scans to plan radiation, potentially have 1-3 small markers placed near the tumor, undergo a tumor biopsy, and receive 5 radiation treatments every other day over a two-week period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will monitor for side effects like gastrointestinal toxicity for up to 3 months after the end of radiation treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
At a glance
Conditions
NCT06984562
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Fox Chase Cancer Center
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Joshua Meyer, MD · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- The rate of acute and late grade ≥3 gastrointestinal toxicity occurring within 3 months of treatment possibly, probably or definitely related to radiation.From start of radiation to 3 months after the end of radiation treatment